Abstract We have designed a tagged probe [sphingolipid binding domain (SBD)] to facilitate the tracking of intracellular movements of sphingolipids in living neuronal cells. SBD is a small peptide consisting of the SBD of the amyloid precursor protein. It can be conjugated to a fluorophore of choice and exogenously applied to cells, thus allowing for in vivo imaging. Here, we present evidence to describe the characteristics of the SBD association with the plasma membrane. Our experiments demonstrate that SBD binds to isolated raft fractions from human neuroblastomas and insect neuronal cells. In protein-lipid overlay experiments, SBD interacts with a subset of glycosphingolipids and sphingomyelin, consistent with its raft association in neurons. We also provide evidence that SBD is taken up by neuronal cells in a cholesterol-and sphingolipid-dependent manner via detergent-resistant microdomains. Furthermore, using fluorescence correlation spectroscopy to assay the mobility of SBD in live cells, we show that SBD's behavior at the plasma membrane is similar to that of the previously described raft marker cholera toxin B, displaying both a fast and a slow component. Our data suggest that fluorescently tagged SBD can be used to investigate the dynamic nature of glycosphingolipid-rich detergentresistant microdomains that are cholesterol-dependent. Previously, cholera toxin B (CtxB) was used to study the intracellular trafficking of raft-borne lipids (4-8). Studies on the uptake mechanisms, intracellular itineraries, and biophysical properties of raft-associated proteins at the plasma membrane have revealed heterogeneity in their trafficking and dynamic behavior (9-12). Currently, very little is known about how different ligands associate with raft domains, to what extent the lipid content in those domains differs, and what effect raft lipids have on intracellular targeting. To begin to answer these questions, it will be necessary to develop a diverse battery of markers to characterize the determinants of binding and trafficking behaviors.
The involvement of cholesterol and sphingolipid-rich membrane microdomains known as lipid rafts in a variety of cellular processes is well established (reviewed in Refs. 1, 2), and raft-borne lipids and proteins have been implicated in several pathological conditions, including neurodegeneration and inflammation (reviewed in Ref. 3) . Previously, cholera toxin B (CtxB) was used to study the intracellular trafficking of raft-borne lipids (4) (5) (6) (7) (8) . Studies on the uptake mechanisms, intracellular itineraries, and biophysical properties of raft-associated proteins at the plasma membrane have revealed heterogeneity in their trafficking and dynamic behavior (9) (10) (11) (12) . Currently, very little is known about how different ligands associate with raft domains, to what extent the lipid content in those domains differs, and what effect raft lipids have on intracellular targeting. To begin to answer these questions, it will be necessary to develop a diverse battery of markers to characterize the determinants of binding and trafficking behaviors.
Here, we present the biochemical and biophysical characterization of a novel, fluorescently tagged sphingolipid binding raft probe, the sphingolipid binding domain (SBD), derived from the amyloid b peptide (Ab). This motif, identified by Fantini (13) in several glycolipidassociated proteins, was postulated to form a V3 loop structure that interacts with the sugar rings in glycosphingolipid head groups. In a separate study (S. Steinert and E. Lee, unpublished data), we showed that fluorescent SBD is targeted to endolysosmal compartments in a cholesterol-dependent manner and that it interacts with raft-like lipid mixtures in liposome binding assays and by surface plasmon resonance.
We used standard raft isolation methods in conjunction with lipid-protein overlays, live cell imaging, and fluorescence correlation spectroscopy (FCS) to describe the characteristics of SBD association with the plasma membrane. Lipid-protein overlay experiments (fat blots) suggest that SBD interacts with particular gangliosides and sphingomyelin, which are generally thought to reside in raft domains. We also demonstrate that SBD interacts predominantly with detergent-insoluble membrane fractions isolated from neuronal cells, similar to other known raft markers. Moreover, its endocytic uptake by neurons is dependent on the presence of intact microdomains, which can be disrupted by cholesterol or sphingolipid depletion. By FCS, we demonstrate that SBD displays mobility characteristics at the plasma membrane that are consistent with partial raft association and shows a distribution of diffusion times strikingly similar to that of CtxB. Pharmacological removal of cholesterol reduced the SBD association with detergent-resistant membranes (DRMs), dependent on cell type. However, in live cell labeling, uptake at the plasma membrane was cholesterol-and sphingolipid-dependent in both neuronal types tested. In summary, we suggest that SBD can serve as a useful tool for the study of cholesterol-dependent sphingolipid membrane microdomains and their trafficking.
METHODS

Cell culture
The Drosophila neuronal cell line DL-DMBG2-c6 (c6; Drosophila Genome Resource Center) (14) was grown at 25jC in Shields and Sang M3 medium (Gibco) with 10% FBS (Gibco), 0.125 IU/ml bovine insulin (Biological Industries), and 1% antibiotic/antimycotic solution (Gibco). NIH 3T3 mouse fibroblasts and SH-SY5Y neuroblastoma (American Type Culture Collection-ATCC) were grown at 37jC in DMEM (Gibco) supplemented with 10% FBS and antibiotic.
One microgram of plasmid DNA was used along with Lipofectamine 2000 (Invitrogen) for transfections according to the manufacturer's instructions. Flotillin-green fluorescent protein (GFP) plasmid (a kind gift from L. Briggs and S. Sweeney) has the flotillin sequence under the control of the Act5c promoter that is constitutively active in Drosophila cells. For use in neuroblastomas, flotillin-GFP was cloned into pcDNA 3.1 (Invitrogen) with cytomegalovirus promoter.
For labeling of free cholesterol with filipin, cells were fixed in 4% paraformaldehyde for 3 min followed by washes in HBSS/ HEPES. Cells were incubated with 50 mg/ml filipin (Sigma) for 45 min and then washed before imaging.
SBD peptide handling and cell labeling SBD peptide linked to an N-terminal cysteine and an inert spacer (cysteine-amino-ethoxy-ethoxy-acetyl[AEEAc]2-DAEFRH-DSGYEVHHQELVFFAEDVG), thiol-coupled with Oregon green (OG) or amine-coupled with tetramethyl rhodamine (TMR) directly to the spacer, was synthesized by Bachem. Myc-tagged SBD was synthesized by GenScript Corp. A mutated sequence (DAEFA-HDSGAEVHHQELVFFAEDVG) and a scrambled sequence (FY-HDESEFGHAVEQFGRDVEAVHDL) were also coupled to myc as controls. To avoid aggregate formation of the peptide, SBD was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Merck), divided into aliquots, and dried. For larger volumes of peptide, evaporation was done under a supply of inert nitrogen. Lyophilized peptide was stored at 220jC and redissolved in DMSO immediately before use. Peptide was diluted to a final working concentration of 10 mM in HBSS (Gibco), supplemented with 10 mM HEPES, incubated at 25jC for 30 min at 10 mM (for Drosophila cells) or at 37jC at 5 mM (for mammalian cells), and then washed three times in HBSS. For lipid overlays/ fat blot experiments, the peptide film obtained after HFIP evaporation was dissolved in DMSO and then in Tris buffer, pH 7.4 (the final concentration of DMSO in buffer did not exceed 1%).
Drug treatments
For cholesterol depletion, cells were incubated in 10 mM methyl-b-cyclodextrin (MbCD; Sigma) for 30 min (in serum-free medium for c6 cells or in medium supplemented with 1% FBS for neuroblastomas) and washed. The Amplex Red Cholesterol Assay kit (Invitrogen) was used to measure cholesterol concentrations in cell extracts before OptiPrep gradient formation and later on the DRM fractions generated.
For sphingolipid depletion, cells were incubated with 10 mM fumonisin B1 (FB1; AG Scientific F1022) for 2 h at 37jC, washed three times with HBSS/HEPES before being labeled with transferrin 594 (Molecular Probes) or CtxB 594 (Molecular Probes) at 37jC for 30 min, and then washed three times with HBSS/ HEPES before being imaged in phenol red-free DMEM/F12 with FB1 (10 mM).
Isolation of DRM fractions
DRMs were isolated as described by Zhai, Chaturvedi, and Cumberledge (15) . Briefly, cells from a confluent plate were washed with phosphate-buffered saline and then resuspended in 0.8 ml of TNET lysis buffer (100 mM Tris, pH 7.5, 20 mM EGTA, 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail; Sigma). The postnuclear supernatant was diluted 1:2 with 60% OptiPrep (Accurate Chemicals and Scientific Corp.). Cell lysate-OptiPrep solution was overlaid with 7.2 ml of 30% and 2.4 ml of 5% OptiPrep solution in a Beckman SW41 tube and centrifuged at 41,000 rpm for 5 h at 4jC. Twelve fractions of 1 ml were collected from the top of the gradient and subjected to routine SDS-PAGE or dot blot analysis.
Immunoblotting
For the lipid-protein overlay assay, Sphingostrips (Invitrogen) were used according to the manufacturers' instructions and protocol as described (16) . Additional sphingolipids (GM1, galactocerebrosides, sphingomyelin, GD1a, GD1b, GT1b, phosphoethanolamine ceramide; Sigma) were spotted onto Hybond C nitrocellulose strips (Amersham) and allowed to dry. These strips were then exposed to 5-20 mM peptides. For dot blots, equal volumes of each fraction were blotted onto nitrocellulose membrane and exposed to antibodies against various raft and nonraft proteins, or 5-10 mM peptide solution in PBST or 1 ng/ml peroxidase-conjugated CtxB (Invitrogen) or 1 mg/ml Lysenin (Peptide Institute).
The following primary antibodies were used: 8C3 (antisyntaxin; Developmental Studies Hybridoma Bank); 9E10 (HRPconjugated, 1:200; Santa Cruz); anti-caveolin (1:1,000; BD Pharmingen); anti-flotillin (1:1,000; Transduction Laboratories); anti-Lysenin (1:1,000; Peptide Institute); and anti-rac (1:250; BD Pharmingen). Primary antibody treatment was followed by peroxidase-conjugated secondary antibody exposure, and then blots were developed using standard chemiluminscent detection (Amersham). Intensity quantification from dot blots was carried out using Quantity-One (Bio-Rad Laboratories) software.
Imaging and FCS
For uptake experiments, images were acquired with a CoolsnapHQ charged coupled device camera on a Deltavision (Applied Precision) wide-field microscope with a 603/1.42 numerical aperture oil lens (Olympus) and a standard filter set (green: excitation, 490/20, emission, 528/38; red: excitation, 555/28, emission 617/73) (Chroma). Quantification of images was performed using the MetaMorph image-processing program as described previously (17) . Whole cell fluorescence was determined by drawing borders around individual cells, and noncellular background was subtracted. All photomicrographs in a given experiment were exposed and processed identically for a given fluorophore.
The FCS instrumental setup used in this study is an Olympus FV300 confocal microscope, with which correlator and Avalanche photo detectors are coupled in house. To excite BODIPY-FL-SM and SBD-OG, a 488 nm argon laser was used, and the emission signal was detected through a 510 AF23 emission filter. Dialkylindocarbocyanine (DiI), CtxB-Alexa-594, and TMR-SBD were excited with a 543 nm He-Ni laser and were detected through a 595 AF60 emission filter. For all measurements, 100 mW laser power before the microscope objective was used. The measurement was carried out as follows: a cell was first imaged in transmitted light, using the XY scan of the Fluoview software of the Olympus confocal system, followed by choosing a region of interest by adjusting the proper Z plane and then performing FCS in the fluorescence point scanning mode. The Avalanche photo detector creates an intensity plot of the fluorescence signal from the sample, and the hardware correlator calculates the autocorrelation function, G(t), expressed as {[yF(t)
2 }, where F(t) is the fluorescence fluctuation caused by a particle at time t and F(t1t) is for the same particle at time point (t1t) (18, 19) . Igor Pro software (version 4) was used to fit the data to the FCS curve-fitting model. The equations for the G(t) fitting models used are as follows: 2D1P1t:
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RESULTS
SBD binds to isolated detergent-insoluble fractions of insect and human neuronal cells Association with DRM fractions has been used as a method to detect raft association (20) . Although DRM binding by itself is insufficient to prove raft association, it is generally considered a necessary criterion. Therefore, we used SBD conjugated to a myc tag to analyze binding to DRMs isolated from different cell types that are spotted onto membranes.
Because our goal is to characterize SBD for the study of lipid trafficking in Drosophila and other cellular neurodegeneration models, we carried out experiments on Drosophila neuronal cells and mammalian neurons. It has been established that DRMs can be isolated from Drosophila embryonic membranes and cell lines and have similar properties to those isolated from mammalian cells (15, 21, 22) . We validate the use of SBD as a raft/sphingolipid tracer by comparing its behavior in the fly neuronal cell line c6 versus SH-SY5Y neuroblastomas, which are susceptible to Ab toxicity (23) .
Drosophila c6 neurons and SH-SY5Y neuroblastomas were solubilized with cold 1% Triton X-100 and fractionated by high-speed centrifugation into detergent-resistant/ insoluble (DRM) and nonresistant/soluble (non-DRM) membrane fractions over an OptiPrep density gradient (see Methods). These fractions were spotted onto membranes and then incubated with SBD-myc. To verify DRM isolation from c6 cells, fractions were assayed for association with a transfected known raft protein, flotillin-GFP, and an endogenous nonraft protein, rac, by Western and dot blots. In c6 cells, flotillin is broadly distributed over DRM fractions; it is present in fraction 3 and somewhat more enriched in fractions 4 and 5 (Fig. 1A) . In contrast, the nonraft protein rac (15) is excluded from fractions 3 and 4 and is found primarily in the more soluble bottom fractions 9 and 10 ( Fig. 1A) . We also used the binding of another raft marker, GM1, to bind CtxB to isolated fractions as an additional criterion for rafts. CtxB binds most prominently to fraction 3 and to a lesser extent to fractions 1 and 2 (Fig. 1B) . Therefore, based on the above four criteria (detergent resistance on a density gradient, presence of flotillin, binding of CtxB, and the exclusion of rac), we define fraction 3 as diagnostic for DRM/raft association in our assay (Fig. 1) . By the same dot blot assay, SBD was seen to bind strongly to raft fraction 3, to a lesser extent to fractions 2 and 4, and also to the more soluble fractions 10 and 11 (Fig. 1B) .
In the neuroblastomas, the raft protein flotillin partitioned preferentially into fractions 3 and 4 and to the more soluble fractions 11 and 12 ( Fig. 1C ). This dual distribution was even more pronounced on the dot blots (Fig. 1D) . The other raft marker, CtxB, also displayed interactions with fractions 1-4 from the top of the gradient and with the more soluble fractions 10 and 11 ( Fig. 1D ). That CtxB profiles are different for the two cell types may be attributable to CtxB binding to different target lipids in fly versus human neurons. Flies do not make GM1, the target of CtxB in mammalian cells (24) , but they do have terminal galactose-bearing glycolipids that could interact weakly with CtxB. From flotillin distribution patterns and CtxB binding, we conclude that there has been a separation of DRMs in fractions 3 and 4. Using the dot blot assay, SBD was seen to bind strongly to DRM fractions 3 and 4 ( Fig. 1D ) in addition to its binding to fractions 5-8. We note that sphingomyelin binding Lysenin (11, 25) , which was used as an additional standard because sphingomyelin is expected to be at least partially raft-localized (26, 27) , bound to non-DRM fractions of neuroblastomas (Fig. 1D ). This does not, however, contradict published data on Lysenin, because its association with DRMs per se has not been reported.
The DRM association of SBD is abrogated by cholesterol depletion in a cell type-dependent manner Next, we examined whether SBD interacts with domains on intact cells that can later be isolated into DRM fractions (Fig. 2) . Cells were incubated with SBD-myc, and subsequently, DRM fractions were isolated and examined for the presence of known raft markers and SBD. Enrichment of cholesterol ( Fig. 2A) , the distribution of raft markers such as flotillin ( Fig. 2B ) and caveolin ( Fig. 2E ), binding to CtxB (Fig. 2C) , and the distribution of the nonraft protein rac indicate successful isolation of DRMs. Based on these criteria, we define fractions 2-4 in c6 cells and fractions 1-4 in neuroblastomas to include DRMs. In both Drosophila c6 cells and neuroblastomas, SBD is taken up in DRM fractions in addition to being taken up in more soluble fractions (Fig. 2D ). Its association with non-DRM fractions is not unusual among bona fide raft markers (e.g., syntaxin in Drosophila membranes, which also follows a broad distribution along the density gradient) (15) . In contrast to the neuronal cell types, SBD did not show a strong preference for uptake via DRM fractions of mammalian NIH 3T3 fibroblasts, segregating roughly equally between the caveolin-positive "raft" fractions (4-6) and the rac-positive "nonraft" fractions (7) (8) (9) (10) (11) (12) (Fig. 2E) .
Treatments that inhibit cholesterol synthesis or that remove cholesterol from membranes are known to disrupt lipid rafts. Therefore, we used MbCD to deplete c6 and Fractions were characterized for the presence of flotillin and the nonraft marker rac using SDS-PAGE and Western blotting. B: Fractions were blotted onto a nitrocellulose membrane and exposed to SBD conjugated to myc (SBD-myc) and cholera toxin B (CtxB). SBD binds to the detergent-resistant fractions 2-4 (C) isolated from c6 cells. It also binds to less dense fractions (10 and 11). CtxB binds to fractions 2 and 3. C: DRM fractions from human neuroblastomas, SH-SY5Y, were isolated as described above. As a control, fractions were assayed for the presence of a raft marker, flotillin, using SDS-PAGE and Western blotting. D: The same fractions used above were blotted onto a nitrocellulose membrane and incubated with SBD-myc, antibody to flotillin, GM1 binding CtxB, and Lysenin. In a profile similar to that of CtxB but in contrast to that of Lysenin, SBD binds primarily to more buoyant, detergent-resistant fractions (3 and 4) but also to intermediate density fractions (5) (6) (7) (8) . Fig. 2 . SBD associates with cholesterol-containing domains of neuronal cells that can be isolated in DRMs. c6 cells (left panels), SH-SY5Y neuroblastomas (right panels), and NIH 3T3 fibroblasts (E) were incubated with SBD-myc for 30 min and then detergent-resistant fractions [fractions 1 (top) to 12 (bottom)] were isolated. Fractions 1-12 were examined for their sterol content (A) and for the distribution of the raft marker flotillin, caveolin (for fibroblasts), and the nonraft marker rac (Western blots; B, E). Fractions 1-12 were blotted onto a membrane and examined for interaction with CtxB (C) and myc immunoreactivity to detect SBD (D). SH-SY5Y and c6 cells were also treated with 10 mM methyl-b-cyclodextrin (MbCD) to deplete cells of cholesterol. In the graphs, dashed lines represent cells treated with MbCD and solid lines represent untreated (control) cells. Line profiles in A depict relative sterol levels measured as fluorescence levels normalized to protein content. Line profiles in C and D depict the relative abundance of SBD-myc (D) and the binding of CtxB (C) in isolated fractions, both measured as intensity of dot blots and combined for successive fractions. In nontreated controls of both neuronal cell types, there is an enrichment of sterols in detergent-insoluble fractions (1-3 for neuroblastomas and 1-6 for c6 cells). Treated cell fractions (dashed) show substantial cholesterol reduction at the top of the gradient compared with the bottom of the gradient. Cholesterol depletion reduced CtxB's interaction with detergent-insoluble fractions in SH-SY5Y neuroblastomas (fractions 1 and 2) and in c6 cells (fractions 1 and 2). In c6 cells (D), fractionation of SBD-myc in DRM fractions 2 and 4 is reduced upon cholesterol depletion. In neuroblastomas, SBD uptake into detergent-resistant fraction 4 appears to be reduced. Detergent-resistant fractions of NIH 3T3 fibroblasts (E) are enriched for lipid raft markers such as caveolin (fractions 3-7) but not for nonraft markers such as rac. SBD is not preferentially taken up into detergent-insoluble fractions of fibroblasts. FU, fluorescence units.
Fluorescent probe SBD interacts with sphingolipids and raft domains
by measuring total cholesterol levels using the Amplex Red Cholesterol Assay method (Invitrogen). On c6 cells, cholesterol was reduced by 46.7 6 7.8% (average of two experiments) after 30 min, and in the neuroblastomas, we observed a reduction of 51.8 6 8.4% (average of two experiments). We also examined the sterol levels across the fractions obtained by density centrifugation ( Fig. 2A, line profiles) . In both cell types used, MbCD treatment causes the distribution of the remaining cholesterol to become more uniform across the density gradient (Fig. 2A) . Also, MbCD treatment results in a larger depletion of cholesterol from the top half than from the bottom half of the gradient. In conjunction with this, the distribution of both raft markers and nonraft markers is altered. Flotillin (Fig. 2B) (Fig. 2C ) also appears to be affected by cholesterol depletion; in the neuroblastomas, CtxB shows diminished interaction with DRM fractions 1 and 2 upon MbCD treatment. Likewise in c6 cells, MbCD treatment causes CtxB's interaction with DRMs (fractions 1 and 2) to be weakened. In addition to the decreased association with DRM fractions 1 and 2 in c6 cells, the raft markers flotillin and CtxB both appear to concentrate in fraction 4 upon cholesterol depletion. Conversely, the nonraft marker rac (Fig. 2B) , which is normally excluded from DRM fractions, appears to now distribute in these fractions (2, 3), suggesting that cholesterol depletion has indeed affected the partitioning of both raft and nonraft proteins in the membrane of c6 cells.
SBD uptake into DRMs is also affected by MbCD treatment. Cholesterol depletion by MbCD caused a reduced uptake of SBD in some of the DRM fractions of c6 cells (fractions 2 and 4) and of neuroblastomas (fraction 4) (Fig. 2D) . Together, these results suggest that the DRM association for SBD is more dependent on cholesterol in some cell types than in others and that some SBD also associates with fractions that do not fulfill the criteria for DRM fractions. SBD's only partial cholesterol dependence for raft association is not unique; another raft marker, flotillin, is also reported to be resistant to cholesterol depletion (28) .
The effect of cholesterol depletion on SBD uptake within 30 min is less dramatic on neuroblastomas than in c6 cells (Fig. 2D) . In light of our observations that SBD is continuously taken up by neuroblastomas, we wondered whether SBD uptake over prolonged time periods is more susceptible to cholesterol depletion in these cells. Our results (see supplementary Fig. I ) indicate that there is no obvious difference in the cholesterol dependence of SBD uptake at 30 or 60 min.
The above data support the conclusion that SBD's membrane association is in general influenced by cholesterol, but depletion of cholesterol does not inhibit its association with DRM-isolatable microdomains equally in all
II).
Cholesterol depletion inhibits SBD uptake
Having determined that cholesterol depletion altered the association of SBD with DRMs, we wanted to find out whether the distribution and uptake of SBD in live cells was detectably altered by cholesterol inhibition. To do this, we imaged SBD-TMR (SBD-TMR) uptake by c6 and SH-SY5Y neurons upon MbCD treatment. Normally, c6 cells internalize SBD within minutes (S. Steinert and E. Lee, unpublished data) (Fig. 3) , leaving little signal at the plasma membrane. In contrast, SBD uptake in MbCDtreated c6 cells was strongly inhibited (Fig. 3A-C) , as indicated by a substantial reduction in the number of internalized SBD-positive spots after cholesterol depletion and more fluorescence at the plasma membrane. Cholesterol depletion was monitored by the assays shown in Fig. 2 and by filipin staining of treated, fixed cells (Fig. 3B, C) . SBD uptake at the plasma membrane of cholesterol-depleted SH-SY5Y neuroblastomas was also strongly disrupted; this is reflected in the lag in uptake (Fig. 3D ) and in the strongly reduced number of cells containing SBD-positive vesicles after 1 h (Fig. 3D-F) . In the same cells, CtxB-Alexa-594 (Invitrogen) also showed a reduced rate of uptake, with a smaller number of internal vesicles, but only after 2 h of cholesterol depletion (data not shown). These results demonstrate that efficient SBD vesicular uptake requires cholesterol (or other sterols) in both Drosophila and mammalian neurons.
FCS analysis of SBD shows plasma membrane mobility characteristic of raft markers
To compare the mobility of SBD on the plasma membrane with that of other raft-and nonraft-associated markers, we carried out FCS measurements on the diffusion rate of SBD-TMR at the plasma membrane of SH-SY5Y neuroblastoma cells. FCS records fluorescence autocorrelation functions, G(t), from a diffraction-limited confocal volume centered on the upper plasma membrane of the cell. Depending on the number of different fluorescent particle species passing through the confocal volume and their location with respect to the plasma membrane, different models may be used to fit G(t), incorporating one or more particles with different mobilities in two or three dimensions (i.e., one particle vs. two particles and two dimensions vs. three dimensions). The diffusion time, t D , is derived from the autocorrelation curve G(t) and gives the time taken by the fluorescent probe to cross the stationary confocal volume. A multiple particle fit will result in a number of diffusion times, which are inversely proportional to the diffusion coefficients. The t D is characteristic of the viscosity in which the membrane probe resides and thus can be used to predict the membrane domain localization of the probe (29) .
Measurements were taken for SBD-TMR, SBD-OG, the raft marker CtxB-Alexa-594, and the nonraft mark-ers DiI-C18 and BODIPY-FL-SM (30, 31) (Fig. 4) . The G(t) functions obtained for these measurements were fitted with a model taking into account the two-dimensional diffusion of two distinct particles and possibly a third particle representing free three-dimensional diffusion of unbound labels. The two two-dimensional diffusing species are interpreted as a faster moving, nonraft-associated population of SBD label in the plasma membrane in addition to a less mobile, raft-associated component. As a control for contributions to G(t) from free label in the medium (outside the cell) or autofluorescence (inside the cell), additional measurements were made outside and inside the cell, with resulting diffusion times of 94 6 2 ms and 2.2 6 0.2 ms, respectively. Values outside the cell are fitted to a three-dimensional, one-particle model, and values inside the cell are fitted to a three-dimensional, two-particle model, as a result of contributions from autofluorescence. Because the correlation time for membrane-associated markers is not expected to be smaller than the millisecond range (the t D for DiI, a typical nonraft membrane probe, was 10 6 0.4 ms) and that for the free label in solution is observed to be in the ?100 ms range, those readings that are dominated by this component were removed from the calculation of average t D .
In agreement with the findings of Schwille and colleagues (29) , measurements of the raft marker CtxB-Alexa-594 were influenced by bleaching effects, presumably as a result of the low mobility of the protein in raft domains (Fig. 4) . The distributions of t D of SBD-TMR and SBD-OG were found to be mainly in the .30 ms category (SBD-TMR, ?70 ms; SBD-OG, ?60 ms on average), with a slightly greater contribution from slow-moving particles than CtxB (?25 ms) (Fig. 5B) . We found that SBD-TMR and SBD-OG measurements, similar to CtxB, were strongly influenced by bleaching. To separate these effects, which artificially bias the t D toward faster moving particles, we expressed the t D frequencies as histograms. In contrast to the longer t D (slower diffusion) of the raft markers, the t D of DiI-C18, a nonspecific lipophilic dye, and BODIPY-FL-SM, a nonraft-localizing sphingolipid analog (32) , were distributed to a large extent between 1 and 20 ms (Fig. 5A) , with the main contribution being 1-10 ms (10 6 0.4 ms for DiI-C18, 10 6 2 ms for BODIPY-FL-SM on average; Fig. 5E ). The histograms also reveal a biphasic Fluorescent probe SBD interacts with sphingolipids and raft domainsdistribution that is strikingly similar for CtxB and SBD-OG, with a slow population diffusing at .30 ms and a slightly larger fast population diffusing mainly between 1 and 10 ms. This is less pronounced for SBD-TMR.
To look at the effects of raft disruption on the mobility of SBD, we measured the t D of SBD as well as the control markers on cells treated with 10 mM MbCD for 30 min. It was found that the diffusion times of DiI and BODIPY-FL-SM under cholesterol depletion remained almost unchanged at 10.7 6 0.6 and 11.5 6 2.9 ms, respectively (Fig. 5E, F) , whereas t D s of SBD were greatly reduced to 5.3 6 0.9 and 2.1 6 0.2 ms for SBD-TMR and SBD-OG, respectively (Fig. 5F ). The average diffusion time of CtxB was also reduced to 11.6 6 0.8 ms, consistent with its raft localization being dependent on cholesterol (Fig. 5F ). These changes are also reflected in the distributions of t D s represented as histograms (Fig. 5C, D) . From the FCS data, we conclude that SBD's diffusion behavior at the plasma membrane is consistent with a substantial fraction being localized in raft domains of low mobility relative to the surrounding membrane.
Sphingolipid depletion inhibits SBD uptake
The SBD motif was postulated to interact with galactoseterminal glycosphingolipids and sphingomyelin (33) , and Ab interactions with gangliosides have been documented extensively (34, 35) . Therefore, we examined with live cell imaging whether the vesicular uptake of SBD requires sphingolipid production in neuroblastomas. Sphingolipid metabolism is disrupted by the mycotoxin FB1, an inhibitor of ceramide synthase (36), a key enzyme in de novo ceramide synthesis. Because glycosphingolipids are synthesized from ceramide, a reduction in ceramide levels should also lead to decreased levels of glycosphingolipids, and inhibition of cellular ganglioside synthesis has indeed been reported upon treatment with FB1 (37, 38) . After treatment with FB1, neuroblastoma cells endocytosed SBD less efficiently and showed fewer internal SBD-positive vesicles ( Fig. 6D ; quantitated in Fig. 6C ) as well as a decrease in total intracellular SBD intensity (quantification shown in supplementary Fig. III) , suggesting that the vesicular uptake of SBD is dependent on sphingolipids or glycosphingolipids.
By comparison, the distribution of the positive control CtxB, which recognizes ganglioside GM1 (39) , is also altered, but apparently uptake is not affected. Instead, CtxB appears to be diverted from its usual Golgi localization (Fig. 6E) . Both of these observations are consistent with the conclusions of Shogomori and Futerman (7), who found that CtxB is raft-localized but that uptake can be raft-independent. In contrast, transferrin-Alexa-594 uptake (Fig. 6A, B) remains unaltered after FB1 treatment. Transferrin was measured on the same cells as a negative control for the FB1 treatment, because transferrin is taken up by clathrin-mediated endocytosis and therefore is not expected to be sphingolipid-dependent (40, 41) .
We also examined SBD uptake in a melanoma strain, GM95 (42) , which is devoid of glycosphingolipids. However, uptake of SBD was extremely inefficient in both the parental/control melanoma cell line, B16, and the mutant GM95 strain (data not shown), such that no conclusions could be drawn about the dependence of SBD uptake on glycosphingolipids in this cell type.
SBD binds to purified glycosphingolipids
Previous in vitro binding studies on SBDs contained in HIV-GP120 and Prp (prion-protein), and Ab(1-40) (13, 33) suggested that the association of these proteins with cell membranes could be mediated by interactions between the SBD and glycosphingolipids at the outer plasma membrane, in particular those containing terminal galactose. For this reason, we were interested in testing whether our myc-tagged SBD could bind to isolated glycosphingolipids. Interaction of SBD with lipids was assayed by lipid-protein overlays (16) in which SBD-myc was incubated with purified lipids immobilized on nitrocellulose membranes. With relatively low amounts of lipid (100 pmoles), SBD Fluorescent probe SBD interacts with sphingolipids and raft domainsrecognized GM1 but not a variety of other glycosphingolipids, glycerophospholipids, or cholesterol (Fig. 7A) . Intact SBD and SBD with a scrambled sequence showed signal for GM1, but much lower than the signal of Lysenin for sphingomyelin (Fig. 7A) or of CtxB on its receptor GM1 (data not shown). However when higher amounts of lipids were used (between 1,000 and 2,000 pmoles), SBD displayed an interaction with galactocerebrosides and gangliosides GD1a and GD1b and, to a much lesser extent, with sphingomyelin (Fig. 7B) . No other lipids or sphingolipids displayed an interaction with SBD, including cholesterol, sulfatide, disialoganglioside, and trisialoganglioside (GM3) (Fig. 7A, B) . Notably, although SBD interacted strongly with bovine galactocerebrosides (consisting of a mixture of both hydroxylated and nonhydroxylated fatty acids) (Fig. 7B) , it showed no affinity for synthetic galactosyl ceramide, which has an essentially identical structure but contains only nonhydroxylated fatty acids. This is not completely unexpected, because another SBD-containing glycoprotein, the HIV-1 surface protein gp120, also displays preferential interaction with synthetic galactosyl ceramide containing hydroxylated fatty acid (43) .
We also examined the interaction of the scrambled version of the peptide and a double mutant version in which amino acids key to the interaction with sphingolipids postulated by Fantini and colleagues (33) were mutated (Fig. 7B) . Surprisingly, the scrambled version of the peptide interacted approximately as well with GD1a, GD1b, and SM as native SBD. This is consistent with the reported binding affinity for target lipids of reverse-sequence Ab40-1 being comparable to, or even exceeding that of, Ab1-40 in SPR measurements (34) . However, in contrast to live cell labeling with native SBD, nearly no uptake was observed with the scrambled SBD peptide (see supplementary Fig. IV) . Our interpretation of these seemingly contradictory results is that SBD may bind weakly to individual gangliosides but more strongly to a specific combination of gangliosides or lipids that we have not yet been able to reproduce on dot blots. SBD may also interact with an unknown protein in the membrane to confer sequence-specific binding.
In contrast, the double mutated version (R5A, Y10A) interacted only with GD1b very weakly and with galactocerebrosides. At higher concentrations, the mutated peptide bound very weakly to GD1a but not to SM. We conclude from this that the interaction between SBD and gangliosides or SM may indeed be mediated at least in part by these two amino acids, as postulated by Fantini and colleagues (33) .
DISCUSSION
We have presented biochemical and pharmacological evidence that a novel fluorescent probe derived from the amyloid peptide Ab, the SBD, associates with plasma membrane microdomains. SBD is taken up by two different neuronal cell types in a cholesterol-and sphingolipiddependent manner.
We show that SBD is associated with microdomains of both fly neuronal cells and mammalian neuroblastomas, but not fibroblasts, and we also observe that its association with DRMs is partly cholesterol dependent in both cell types, with fly neurons being more sensitive to cholesterol depletion. In light of this, it is interesting that sphingolipids in flies are structurally different from their mammalian counterparts (24) . Although flies do not produce sphingomyelin or gangliosides such as GM1, they have other terminal galactose-containing glycolipids (44) and an analog of sphingomyelin, phosphoethanolamine ceramide, that could also be cleaved by sphingomyelinases (22; Julie Saba, personal communication). These fly sphingolipids could be involved in cholesterol dependent SBD uptake.
We also analyzed the biophysical characteristics of SBD's association with the plasma membrane by examining its diffusion dynamics with FCS in human neuroblastomas. In this study, the t D s of the nonraft markers (DiI and BODIPY-FL-SM) were distributed within a comparatively narrow range, unlike the raft markers, which were distributed in a very wide range of t D values. However, the clustering of the histogram of SBD t D values around .30 ms and ?1-10 ms is consistent with the estimates of . SBD interacts with purified glycosphingolipids. A: Lipid-protein overlay assay using Sphingostrips (Invitrogen) prespotted with lipids and exposed to SBD-myc, SBD with a scrambled sequence (SBD-scr)-myc, and Lysenin. SBD-myc and SBD-scr-myc interact with monosialoganglioside (GM1). Lysenin recognizes its known target, sphingomyelin (SM). GD3, disialoganglioside; Sf, sulfatide; Sgal, sphingosylgalactoside; Ch, cholesterol; LPC, lysophoshatidylcholine; PC, phosphatidylcholine; BL, blank; Sph, sphingosine; S1P, sphingosine-1-phosphate; PSp, phytosphingosine; Cer, ceramide; SPC, sphingosylphosphocholine; LPA, lysophosphatidic acid; M, myriocin. B: Lipid-protein overlay assay using membrane strips spotted with additional sphingolipid standards and then exposed to SBDmyc (5 and 20 mM), SBD mutated (SBD**)-myc, and SBD-scr-myc. SBD-myc and SBD-scr-myc bind to GD1a, GD1b, and galactocerebrosides. SBD-myc weakly interacts with SM at higher concentrations (20 mM). Double mutated (R5A, Y10A) SBD**-myc fails to show any interaction with GD1a and SM at 5 mM. At higher concentrations (20 mM), it fails to show any interaction with SM and only weakly interacts with GD1a, GD1b, and GT1b. GD1a, disialoganglioside 1a; GD1b, disialoganglioside 1b; GT1b, trisialoganglioside GT1b; GalCer, galactosyl ceramide; PE-Cer, phosphoethanolamine ceramide; CB, galactosylcerebroside.
Fluorescent probe SBD interacts with sphingolipids and raft domains Sharma et al. (45) that 60-80% of a raft-associated glycosylphosphatidylinositol-linked protein is actually present in the nonraft fraction. The very similar biphasic distribution of diffusion times for SBD (in particular SBD-OG) and CtxB may reflect the existence of two distinct populations at the plasma membrane, one of which is associated with the liquid-ordered phase and the other not. Indeed, from our fractionation experiments, we observe that SBD is also taken up by membrane components that do not fit within the operative definition for rafts, namely, detergent insolubility. This mixed distribution is observed by us and other authors for a number of presumed raft-associated proteins (46) .
It is interesting that although the clustered histogram distribution of t D values of CtxB was very similar to those of SBD, especially SBD-OG, the average t D for this established raft marker was shorter on average than those of SBD (Fig. 5B) . This may indicate that CtxB and SBD are both at least partially raft-associated but that the dynamic nature of their resident domains is different. Raftassociated markers are expected to be bleached, because they are less mobile than the surrounding nonraft membrane and thus are unable to leave the focus (47, 48) . Accordingly, we see a major bleaching component in our measurements of SBD and CtxB. The extremely slow mobile fraction observed for SBD and CtxB compared with DiI, therefore, suggests their association to raft-like structures or cross-linked raft assemblies.
Drugs that remove cholesterol from the plasma membrane are known to inhibit the trafficking of lipid raft markers and have been used extensively as tools to differentiate between raft-and nonraft-mediated processes (47, 49) . Both biochemical and cell-labeling studies indicate a cholesterol-dependent uptake of SBD. However, this difference is more obvious in the c6 cells than in the neuroblastomas. Using FCS on neuroblastomas, under cholesterol depletion, the influence of bleaching on the autocorrelation function is in fact removed, and we find a large change in t D value for SBD. The shift is toward nonraft-like fast diffusion times. This is similar to the effect on the raft marker CtxB, whereas the nonraft markers did not show any significant change (29) . Taking into consideration both the DRM isolation data and the FCS results, we conclude that SBD is still able to associate to some extent with the more buoyant membrane fractions, even in the absence of cholesterol and diffusing at nonraft speeds.
In a separate study, we showed that SBD interacts with ganglioside-containing liposomes of raft-like composition (S. Steinert and E. Lee, unpublished data). Here, we used a more sensitive (50) lipid-protein overlay (fat blot) assay to assess SBD's ability to bind specific lipids. Among the sphingolipids we tested by lipid-protein overlay, SBD bound to galactocerebrosides and to GD1a, GD1b, and GM1 but not to other sphingolipids. SBD's affinity for glycosphingolipids, but not cholesterol, glycerophospholipids, or sphingoid bases, is consistent with the original model of Fantini and coworkers (33) that SBD binds to rafts primarily via an interaction with raft-borne glycosphingolipid head groups.
SBD also displayed a weak interaction with sphingomyelin. Interestingly, a double mutation (in which arginine 5 and tyrosine 10 are both switched to alanine) eliminated the interaction with sphingomyelin. This supports the prediction (13) that secondary electrostatic interactions involving basic charged residues such as lysine and arginine with the negatively charged phosphate group of sphingomyelin are also possible. The same double mutant also affected SBD's ability to bind gangliosides, again supporting the model of Fantini and coworkers (33) , in which aromatic amino acids in the V3 loop engage in p-bonding with galactose found in galactose-containing head groups. In addition, all three peptides interact with brain-derived galactocerebrosides but not galactosyl ceramide. In light of our liposome-capture experiments (S. Steinert and E. Lee, unpublished data), however, in which SBD did not bind galactocerebrosides, it seems likely that this interaction is not physiological and may occur only when the lipids are not presented in a bilayer.
In a separate study (S. Steinert and E. Lee, unpublished data) using quantitative time-lapse imaging, we characterized the intracellular trafficking pathway of SBD and showed that it could interact with a number of different cell types and certain glycolipids in liposome-capture experiments. The current studies used three approaches to describe SBD's behavior at the plasma membrane. First, we used lipid-protein interaction assays with DRM fractions and fat blots to determine SBD's affinity for raft-type lipids. Second, pharmacological inhibitor studies were used to test the cholesterol and glycosphingolipid dependence of SBD uptake at the membrane. Finally, we used FCS to show that SBD displays a low mobility at the membrane, characteristic of raft-associated markers. These studies, along with the intracellular trafficking characerization, establish SBD as a novel fluorescent tracer for cholesterol-dependent, glycosphingolipid-containing microdomains in living cells.
